Finch Therapeutics Group Inc (FNCH)

$2.33

+0.3

(+14.78%)

Live

Insights on Finch Therapeutics Group Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 8.0K → 107.0K (in $), with an average increase of 92.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.41M → -3.04M (in $), with an average decrease of 25.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 130.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 248.2% return, outperforming this stock by 347.8%

Performance

  • $1.97
    $2.34
    $2.33
    downward going graph

    15.45%

    Downside

    Day's Volatility :15.81%

    Upside

    0.43%

    downward going graph
  • $1.86
    $16.74
    $2.33
    downward going graph

    20.17%

    Downside

    52 Weeks Volatility :88.89%

    Upside

    86.08%

    downward going graph

Returns

PeriodFinch Therapeutics Group IncSector (Health Care)Index (Russel 2000)
3 Months
-33.88%
-1.1%
0.0%
6 Months
-53.76%
6.7%
0.0%
1 Year
-82.66%
3.2%
-0.7%
3 Years
-99.59%
15.2%
-21.6%

Highlights

Market Capitalization
3.3M
Book Value
$14.25
Earnings Per Share (EPS)
-46.59
Wall Street Target Price
90.0
Profit Margin
0.0%
Operating Margin TTM
-31777.57%
Return On Assets TTM
-19.47%
Return On Equity TTM
-126.06%
Revenue TTM
107.0K
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-57.0M
EBITDA
-32.5M
Diluted Eps TTM
-46.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Finch Therapeutics Group Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3762.66%

Current $2.33
Target $90.00

Technicals Summary

Sell

Neutral

Buy

Finch Therapeutics Group Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
-20.55%
-53.76%
-82.66%
-99.59%
-99.68%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
NA
NA
NA
0.0
-1.26
-0.19
NA
14.25
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.75
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.03
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.46
46.46
2.4
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.62
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
Buy
$3.3M
-99.68%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.3B
140.93%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$564.6B
394.48%
46.46
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.5B
117.3%
28.57
36.68%

Institutional Holdings

  • Baupost Group LLC

    4.19%
  • Susquehanna International Group, LLP

    3.68%
  • Avenir Management Co., LLC

    2.84%
  • Vanguard Group Inc

    2.41%
  • Renaissance Technologies Corp

    0.73%
  • Ikarian Capital, LLC

    0.43%

Corporate Announcements

  • Finch Therapeutics Group Inc Earnings

    Finch Therapeutics Group Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

finch therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. we use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. this human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. this enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients’ lives.

Organization
Finch Therapeutics Group Inc
Employees
1
CEO
Mr. Matthew P. Blischak J.D.
Industry
Healthcare

FAQs